WHO Gives Nod To Biological E As Additional Production Site For Johnson & Johnson Covid Vaccine Janssen

The Hyderabad-based company will become an additional manufacturing site for the single-shot Covid vaccine Janssen.  

Johnson & Johnson's Janssen Covid-19 vaccine

Source : AFP

Covid Vaccine Update: India's race to fight against coronavirus got strengthened further as the World Health Organization (WHO) gave approval to Biological E to manufacture Johnson & Johnson's COVID-19 vaccine. The Hyderabad-based company will become an additional manufacturing site for the single-shot Covid vaccine Janssen.  

Congratulating the pharma company over the same, the US embassy in India tweeted on Wednesday, "Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine."

"Great progress for the Quad Vaccine and US India Health partnerships through US technical support and @DFCgov financing," the US embassy in India further said in a tweet.

Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing. pic.twitter.com/u35eU9YhZZ

— U.S. Embassy India (@USAndIndia) June 22, 2022

Biological E is the manufacturer of the coronavirus vaccine Corbevax, India's first indigenously developed RBD protein subunit vaccine, which is currently being used to inoculate children in the age group of 12 to 14 years. The Drugs Controller General of India (DCGI) recently approved Corbevax as a precaution dose for those aged 18 and above. 

Meanwhile, Biological E is awaiting a communication from the WHO for the next round of the approval process to get an emergency use listing (EUL) for Corbevax. EUL from the WHO will pave way for wider acceptance and quicker adoption of the vaccine, especially in countries with limited regulatory facilities.

(With PTI Inputs)